JP2024156878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024156878A5 JP2024156878A5 JP2024127876A JP2024127876A JP2024156878A5 JP 2024156878 A5 JP2024156878 A5 JP 2024156878A5 JP 2024127876 A JP2024127876 A JP 2024127876A JP 2024127876 A JP2024127876 A JP 2024127876A JP 2024156878 A5 JP2024156878 A5 JP 2024156878A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- abc
- klrg1
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 10
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 102000000905 Cadherin Human genes 0.000 description 6
- 108050007957 Cadherin Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732329P | 2018-09-17 | 2018-09-17 | |
| US62/732,329 | 2018-09-17 | ||
| JP2021539334A JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
| PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Division JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024156878A JP2024156878A (ja) | 2024-11-06 |
| JP2024156878A5 true JP2024156878A5 (enExample) | 2025-01-29 |
Family
ID=69887899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12365735B2 (enExample) |
| EP (1) | EP3852779A4 (enExample) |
| JP (2) | JP7654548B2 (enExample) |
| KR (1) | KR20210060477A (enExample) |
| CN (2) | CN112752580B (enExample) |
| AU (1) | AU2019344524A1 (enExample) |
| BR (1) | BR112021004553A2 (enExample) |
| CA (1) | CA3113069A1 (enExample) |
| EA (1) | EA202190647A1 (enExample) |
| IL (2) | IL281594B1 (enExample) |
| MX (2) | MX2021003119A (enExample) |
| SG (1) | SG11202102114UA (enExample) |
| WO (1) | WO2020060781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7654548B2 (ja) | 2018-09-17 | 2025-04-01 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗ｋｌｒｇ１抗体 |
| US20230331853A1 (en) * | 2020-09-11 | 2023-10-19 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| EP2314618A3 (en) | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| AU2006204791A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
| NZ600281A (en) | 2006-12-27 | 2013-03-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| DK2462161T3 (en) | 2009-08-06 | 2017-06-06 | Immunas Pharma Inc | Antibodies specifically binding to A-beta oligomers and their use |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| SG188285A1 (en) * | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| WO2012145746A1 (en) | 2011-04-21 | 2012-10-26 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
| RU2616881C2 (ru) | 2011-06-06 | 2017-04-18 | Ново Нордиск А/С | Терапевтические антитела |
| JPWO2012176765A1 (ja) | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| KR102266819B1 (ko) | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| TWI681972B (zh) | 2014-03-19 | 2020-01-11 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途 |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| JP7074665B2 (ja) | 2015-10-07 | 2022-05-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野 |
| CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| EP3471539A4 (en) * | 2016-06-03 | 2020-02-26 | The Brigham and Women's Hospital | KLRG1 SIGNALING THERAPY |
| WO2018053264A2 (en) * | 2016-09-16 | 2018-03-22 | The Brigham And Women's Hospital, Inc. | Klrg1 depletion therapy |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US11584790B2 (en) | 2017-04-14 | 2023-02-21 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| CN111093702A (zh) | 2017-06-22 | 2020-05-01 | 财团法人生物技术开发中心 | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 |
| WO2019169229A1 (en) | 2018-03-01 | 2019-09-06 | Nextcure, Inc. | Klrg1 binding compositions and methods of use thereof |
| JP7654548B2 (ja) | 2018-09-17 | 2025-04-01 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 抗ｋｌｒｇ１抗体 |
| MX2021012171A (es) | 2019-04-09 | 2021-12-10 | Abcuro Inc | Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
-
2019
- 2019-09-06 JP JP2021539334A patent/JP7654548B2/ja active Active
- 2019-09-06 KR KR1020217008068A patent/KR20210060477A/ko active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 CN CN201980060735.4A patent/CN112752580B/zh active Active
- 2019-09-06 AU AU2019344524A patent/AU2019344524A1/en active Pending
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en not_active Ceased
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
- 2019-09-06 IL IL281594A patent/IL281594B1/en unknown
- 2019-09-06 CN CN202411978380.6A patent/CN119638835A/zh active Pending
- 2019-09-06 US US17/285,793 patent/US12365735B2/en active Active
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
-
2021
- 2021-03-16 MX MX2025008993A patent/MX2025008993A/es unknown
-
2024
- 2024-08-02 JP JP2024127876A patent/JP2024156878A/ja active Pending
-
2025
- 2025-09-04 IL IL323170A patent/IL323170A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156878A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| US20240417470A1 (en) | Fusions with cd8 antigen binding molecules for modulating immune cell function | |
| JP6621778B2 (ja) | ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
| JP6526189B2 (ja) | 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用 | |
| TWI373343B (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
| JP2024150751A5 (enExample) | ||
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| CA3142738A1 (en) | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function | |
| JP2018533371A5 (enExample) | ||
| KR20170012347A (ko) | 삼중-특이적 결합 분자 및 그것의 사용 방법 | |
| CN110662768B (zh) | 治疗性抗cd40配体抗体 | |
| JPWO2019152742A5 (enExample) | ||
| TW201632559A (zh) | 結合ｃｄ１３７之抗體治療劑 | |
| JP2020511947A5 (enExample) | ||
| KR20110103431A (ko) | 미오스타틴 결합 단백질 | |
| TWI814715B (zh) | Ａｄａｍ９結合分子及使用其的方法 | |
| RU2006111579A (ru) | Антитела к рецептору интерлейкина-1 и их применение | |
| JP2019524100A5 (enExample) | ||
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| CN116390953A (zh) | 靶向人密蛋白18.2的抗体及其用途 | |
| WO2022125712A9 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| TW202233674A (zh) | 用於調節δγ鏈介導之免疫的組成物及方法 | |
| CN115335405A (zh) | 全人源抗人cd22的嵌合抗原受体及其应用 | |
| CN116262790A (zh) | 嵌合的抗cd27抗体组合物及其应用 |